STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [Form 4] Keros Therapeutics, Inc. Insider Trading Activity

Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock in an open‑market transaction at a weighted average price of $10.19 per share. After this buy, he directly holds 17,592 common shares. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre‑scheduled rather than a discretionary trade.

Positive

  • None.

Negative

  • None.
Insider BIENAIME JEAN JACQUES
Role null
Bought 1,000 shs ($10K)
Type Security Shares Price Value
Purchase Common Stock 1,000 $10.19 $10K
Holdings After Transaction: Common Stock — 17,592 shares (Direct, null)
Footnotes (1)
  1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Shares purchased 1,000 shares Open-market common stock buy on 2026-06-15
Weighted average price $10.19 per share Price for 1,000-share open-market purchase
Post-transaction holdings 17,592 shares Common stock directly owned after transaction
Trade price range $9.99–$10.34 per share Range of individual executions for purchased shares
Plan adoption date December 5, 2025 Rule 10b5-1 trading plan adoption by reporting person
Rule 10b5-1 trading plan regulatory
"Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BIENAIME JEAN JACQUES
(Last)(First)(Middle)
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026P(1)1,000A$10.19(2)17,592D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.99 to $10.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Esther Cho, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Keros Therapeutics (KROS) disclose in this Form 4?

Keros Therapeutics reported that director Jean Jacques Bienaime bought 1,000 shares of common stock. The open‑market purchase occurred at a weighted average price of $10.19 per share and was executed under a pre‑arranged Rule 10b5-1 trading plan adopted in December 2025.

At what price did the Keros Therapeutics (KROS) director purchase shares?

The director’s purchase is reported at a weighted average price of $10.19 per share. Footnotes explain the 1,000 shares were bought in multiple trades within a price range from $9.99 to $10.34, all as part of a pre‑scheduled Rule 10b5-1 trading plan.

How many Keros Therapeutics (KROS) shares does the insider hold after this transaction?

Following this open‑market buy, Jean Jacques Bienaime directly holds 17,592 shares of Keros Therapeutics common stock. This total reflects adding the 1,000 newly purchased shares to his prior position, as reported in the Form 4’s post‑transaction ownership column for non‑derivative securities.

Was the Keros Therapeutics (KROS) insider trade made under a Rule 10b5-1 plan?

Yes. A footnote states the 1,000 Keros shares were purchased pursuant to a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on December 5, 2025, indicating the trades were pre‑scheduled rather than timed in response to recent market developments.

What does the reported price range mean for the Keros Therapeutics (KROS) insider purchase?

The Form 4 shows a weighted average price of $10.19 but notes trades occurred between $9.99 and $10.34. This means the 1,000 shares were bought in multiple executions inside that range, and detailed per‑price information is available upon request from the issuer or the SEC staff.